These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16043749)

  • 1. Impaired absorption of insulin aspart from lipohypertrophic injection sites.
    Johansson UB; Amsberg S; Hannerz L; Wredling R; Adamson U; Arnqvist HJ; Lins PE
    Diabetes Care; 2005 Aug; 28(8):2025-7. PubMed ID: 16043749
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical aspects of Insulin Lispro (LY275585)].
    Kuzuya T
    Nihon Rinsho; 1997 Nov; 55 Suppl():298-305. PubMed ID: 9434484
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes.
    Becker RH; Frick AD; Nosek L; Heinemann L; Rave K
    Diabetes Care; 2007 Oct; 30(10):2506-7. PubMed ID: 17675541
    [No Abstract]   [Full Text] [Related]  

  • 4. [Insulin aspart].
    Namba M
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():492-7. PubMed ID: 12387040
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart.
    Ihlo CA; Lauritzen T; Sturis J; Skyggebjerg O; Christiansen JS; Laursen T
    Diabet Med; 2011 Feb; 28(2):230-6. PubMed ID: 21219436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Taking the peak out of blood pressure. Diabetics can also live spontaneously].
    MMW Fortschr Med; 1999 Dec; 141(49-50):66-7. PubMed ID: 10726151
    [No Abstract]   [Full Text] [Related]  

  • 7. Intraperitoneal insulin therapy for a patient with type 1 diabetes with insulin injection site inflammation.
    Lee SI; Narendran P
    BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25188930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes.
    Hedman CA; Lindström T; Arnqvist HJ
    Diabetes Care; 2001 Jun; 24(6):1120-1. PubMed ID: 11375381
    [No Abstract]   [Full Text] [Related]  

  • 9. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract]   [Full Text] [Related]  

  • 10. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.
    Plank J; Wutte A; Brunner G; Siebenhofer A; Semlitsch B; Sommer R; Hirschberger S; Pieber TR
    Diabetes Care; 2002 Nov; 25(11):2053-7. PubMed ID: 12401756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.
    Lindholm A; McEwen J; Riis AP
    Diabetes Care; 1999 May; 22(5):801-5. PubMed ID: 10332685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes.
    Bolli GB; Luzio S; Marzotti S; Porcellati F; Sert-Langeron C; Charbonnel B; Zair Y; Owens DR
    Diabetes Obes Metab; 2011 Mar; 13(3):251-7. PubMed ID: 21205115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.
    Ma Z; Parkner T; Frystyk J; Laursen T; Lauritzen T; Christiansen JS
    Diabetes Technol Ther; 2012 Jul; 14(7):589-95. PubMed ID: 22519735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections.
    Mortensen H; Kocova M; Teng LY; Keiding J; Bruckner I; Philotheou A
    Pediatr Diabetes; 2006 Feb; 7(1):4-10. PubMed ID: 16489968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
    Heise T; Eckers U; Kanc K; Nielsen JN; Nosek L
    Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensifying insulin therapy with insulin analog premixes: transitioning from basal insulin in type 2 diabetes.
    Shanik MH
    Diabetes Technol Ther; 2012 Jun; 14(6):533-9. PubMed ID: 22364142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [From human insulin to designer insulin. Why insulin analogs?].
    Jungmann E
    Fortschr Med; 1997 Apr; 115(12):40-1. PubMed ID: 9235302
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current insulin therapy. Treatment with new short-acting and retard insulin analogs].
    Matthaei S; Hamann A
    Fortschr Med; 1997 Apr; 115(12):35-6, 39. PubMed ID: 9235301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.
    Porcellati F; Rossetti P; Ricci NB; Pampanelli S; Torlone E; Campos SH; Andreoli AM; Bolli GB; Fanelli CG
    Diabetes Care; 2007 May; 30(5):1261-3. PubMed ID: 17303785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.